Jennison Associates
PACB icon

Jennison Associates’s Pacific Biosciences PACB Stock Holding History

Jennison Associates’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-229,794
Closed -$303K – 610
2026
Q1 		$303K Buy
+229,794
New +$411K ﹤0.01% 556
2023
Q3 		– Sell
-59,408
Closed -$790K – 594
2023
Q2 		$790K Sell
59,408
-17,580
-23% -$214K ﹤0.01% 512
2023
Q1 		$892K Sell
76,988
-1,700
-2% -$16.9K ﹤0.01% 507
2022
Q4 		$644K Sell
78,688
-98,604
-56% -$850K ﹤0.01% 544
2022
Q3 		$1.03M Buy
177,292
+24,127
+16% +$138K ﹤0.01% 504
2022
Q2 		$677K Buy
153,165
+70,949
+86% +$431K ﹤0.01% 567
2022
Q1 		$748K Buy
+82,216
New +$947K ﹤0.01% 597

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jennison Associates's PACB Position: Q2 2026 in Review

Jennison Associates sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 229,794 shares — an estimated $303K sold.

Jennison Associates first reported a position in PACB in Q1 2022 and held it in 7 quarters. The position peaked at $1.03M in Q3 2022. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Jennison Associates reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
  • Jennison Associates sold 229,794 Pacific Biosciences shares in Q2 2026, an estimated $303K.
  • Jennison Associates first reported a position in Pacific Biosciences in Q1 2022 and held it in 7 quarters.
  • Jennison Associates's Pacific Biosciences position peaked at $1.03M in Q3 2022.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.